Title of article :
A Possible Guide as a Tool to Complementary Effects of New Coronavirus
Author/Authors :
Sadremomtaz ، Afsaneh Groningen Research Institute of Pharmacy - University of Groningen , Hashemi ، Javad Department of Pathobiology and Laboratory Sciences - School of Medicine - North Khorasan University of Medical Sciences , Sahebnasagh ، Adeleh Department of Internal Medicine - Clinical Research Center, School of Medicine - North Khorasan University of Medical Sciences , Nabavi ، Mohammad Baqiyatallah Hospital - Baqiyatallah University of Medical Sciences , Al-Dahmani ، Zayana M. XB20 Drug Design, Groningen Research Institute of Pharmacy - University of Groningen , Gheibi ، Shayesteh Department of Clinical Pharmacy - School of Pharmacy - Tehran University of Medical Sciences , Shahrami ، Bita Department of Clinical Pharmacy - School of Pharmacy - Tehran University of Medical Sciences , Mosaed ، Reza Department of Anesthesiology and Intensive Care - School of Medicine - Aja University of Medical Sciences , Arfa ، Peyman Burn Intensive Care Unit - Shahid Motahari Burn Hospital - Iran University of Medical Sciences , Roshanzamiri ، Soheil Burn Intensive Care Unit - Shahid Motahari Burn Hospital - Iran University of Medical Sciences , Mojtahedzadeh ، Mojtaba Department of Clinical Pharmacy - Pharmaceutical Sciences Research Center - Tehran University of Medical Sciences
Abstract :
At the end of 2019, Sars-CoV-2 was identified and has since spread in the world. Coronavirus is commonly caused by upper respiratory tract and severe acute respiratory syndrome in humans. Due to the novel nature of the virus and high mortality among high-risk people, today health care providers used several medications with different mechanisms to overcome this virus. The course of COVID-19 represents three stages that have different symptoms and used different drugs depends on each stage. Ultimately the minority of patients progress to stage III with high mortality. The aim of this study is a comprehensive review of COVID-19 adjuvant therapies. We explained the current study on the use of Glucocorticoids, Interferon, Vitamin C, Tocilizumab, Anakinra, Pentoxifylline, IVIG, Allopurinol, Ivermectin, and Selenium in sepsis, pneumonia, and ARDS and we suggested a new protocol for prescribing each medication currently used in COVID-19 Outbreak.
Keywords :
Sars , CoV , 2 , Drugs , adjuvant therapies
Journal title :
Archives of Anesthesiology and Critical Care
Journal title :
Archives of Anesthesiology and Critical Care
